Ultragenyx Pharmaceutical RARE Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's interest income?
- Ultragenyx Pharmaceutical (RARE) reported interest income of $6M in Q1 2026.
- How has Ultragenyx Pharmaceutical's interest income changed year-over-year?
- Ultragenyx Pharmaceutical's interest income decreased by 14.3% year-over-year, from $7M to $6M.
- What is the long-term trend for Ultragenyx Pharmaceutical's interest income?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's interest income has grown at a 90.1% compound annual growth rate (CAGR), from $1.93M to $25.17M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.